Neutral
0.0
Last updated: 2026-03-07 15:43:10 ET
ABBV's neuroscience unit delivered $10.8B in 2025 and can hit $12.5B in 2026 as Vyalev gains traction and new Parkinson's drug tavapadon awaits FDA re...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE